• X4 Pharmaceuticals appointed CAMP4 Therapeutics CFO Kelly Gold to its board, effective July 1, 2026.
• Gold joins as an independent director, taking a seat on the audit committee.
• She previously held corporate finance and business planning roles at Biogen, supporting late-stage and marketed rare disease programs.
• Earlier in her career, she worked in healthcare investment banking at Deutsche Bank.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. X4 Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607010700PRIMZONEFULLFEED9755224) on July 01, 2026, and is solely responsible for the information contained therein.